Mineralocorticoids and Hypertension

1. Front Matter

   Pages I-XVII

   PDF

2. Physiological Basis of Mineralocorticoid Hormone Action

   1. Front Matter

      Pages 1-1

      PDF

   2. Mineralocorticoid Receptors and Extrinsic Specificity-conferring Mechanisms

      • Z. Krozowski, G. Stephenson, S. Quirk, J. Funder

      Pages 3-9

   3. Intracellular Action of Mineralocorticoids: The Role of the Flavin Coenzymes and Riboflavin Analogs in Hypertension

      • D. Trachewsky

      Pages 10-26

3. Regulation of Mineralocorticoids

   1. Front Matter

      Pages 27-27

      PDF

   2. Novel Control Mechanisms of Aldosterone Secretion

      • C. R. W. Edwards, E. A. S. Al-Dujaili, B. C. Williams

      Pages 29-40

   3. The Diagnostic Value of Urinary Free 18-Hydroxycorticosterone in Primary Aldosteronism

      • S. Abdelhamid, P. Vecsei, N. Panitz, H. L. Christl

      Pages 41-50

   4. Acute and Chronic Regulation of Aldosterone Secretion in Man

      • W. Oelkers, M. Schöneshöfer

      Pages 51-61

   5. Radioimmunologie Methods in Aldosterone Diagnosis

      • P. Vecsei, S. Abdelhamid, P. Bubel, D. Haack, S. Lewicka, K. Lichtwald et al.

      Pages 62-77

4. Pathophysiological Aspects of Mineralocorticoid Excess

   1. Front Matter

      Pages 79-79

      PDF

   2. Mechanism for Escape from the Sodium-retaining Effects of Mineralocorticoids

      • F. G. Knox, J. C. Romero

      Pages 81-100

   3. Mechanism of Mineralocorticoid-induced Hypertension

      • J. Mitchell, D. F. Bohr

      Pages 101-112

   4. The Role of “Mineralocorticoids”, “Glucocorticoids” and “Hypertensinogenic” Steroids in ACTH-induced Hypertension

      • B. A. Scoggins, A. Butkus, J. P. Coghlan, D. A. Denton, R. T. Mason, P. J. Meehan et al.

      Pages 113-128

   5. Mechanism of Mineralocorticoid-induced Hypertension in Man

      • T. Philipp, B. Lüth, G. Wucherer, A. Distler

      Pages 129-139

5. Clinical Aspects of Mineralocorticoid-induced Hypertension

   1. Front Matter

      Pages 141-141

      PDF

   2. Primary Aldosteronism and Other Mineralocorticoid Excess Syndromes in Hypertension: Incidence, Screening, and Diagnosis

      • F. Skrabal, G. Finkenstedt, R. Gasser, G. Bartsch, W. Zechmann

      Pages 143-154

   3. Differentiation of Mineralocorticoid-induced Hypertension

      • D. C. Kem, R. D. Brown, R. Painton, C. Hanson, D. Lyons, M. Weinberger et al.

      Pages 155-166

   4. Localization of te Adrenal Lesions in Primary Aldosteronism

      • M. Fischer, W. Vetter, M. Galanski, B. Winterberg, H. Vetter

      Pages 167-177

   5. Is Idiopathic Hyperaldosteronism a Variant of Essential Hypertension or of Conn’s Syndrome?

      • A. Lasaridis, D. L. Davies, C. Beretta-Piccoli, J. J. Brown, R. Fraser, C. Holloway et al.

      Pages 178-186

   6. Mineralocorticoids in Essential Hypertension

      • A. Helber, G. Wambach, W. Hummerich, K. A. Meurer

      Pages 187-196

On behalf of the organizing committee of this symposium, I would like to wel­ come you to Cologne and thank you very much for coming. We appreciate that some of the leading scientists in the field of hypertension have accepted our invi­ tation to participate actively at this conference. Our first symposium on renin-angiotensin, aldosterone, and hypertension took place at Titisee in the Black Forest in 1967. The second one, on the renin-angio­ tensin-aldosterone system under the influence of therapeutic procedures, was held at the same place in 1970. Five years later in 1975 at a third symposium in Cologne, we discussed the problems of central nervous control of sodium balance in relation to the renin-angiotensin system. The symposium about to begin is devoted to the significance of mineralocorti­ coids in developing and sustaining arterial hypertension. 1) In order to provide a physiologic background for the understanding of the mechanisms involved in this complicated process, new concepts on the regulation of mineralocorticoid secretion must be discussed in detail. As the most important mineralocorticoid, aldosterone is regulated by changes in sodium and potassium homeostasis and is also influenced by adrenocorticotropic hormone (ACTH).

• Hypertonie
• Mineralokortikoide
• hypertension
• hypertonia
• kidney

• Medizinische Klinik Köln-Merheim und Poliklinik der Universität, Köln 91, Federal Republic of Germany

  Werner Kaufmann, Gerhard Wambach, Albert Helber, Karl-August Meurer

Policies and ethics